899 related articles for article (PubMed ID: 20632993)
1. Crystal structure of the ALK (anaplastic lymphoma kinase) catalytic domain.
Lee CC; Jia Y; Li N; Sun X; Ng K; Ambing E; Gao MY; Hua S; Chen C; Kim S; Michellys PY; Lesley SA; Harris JL; Spraggon G
Biochem J; 2010 Sep; 430(3):425-37. PubMed ID: 20632993
[TBL] [Abstract][Full Text] [Related]
2. Unique substrate specificity of anaplastic lymphoma kinase (ALK): development of phosphoacceptor peptides for the assay of ALK activity.
Donella-Deana A; Marin O; Cesaro L; Gunby RH; Ferrarese A; Coluccia AM; Tartari CJ; Mologni L; Scapozza L; Gambacorti-Passerini C; Pinna LA
Biochemistry; 2005 Jun; 44(23):8533-42. PubMed ID: 15938644
[TBL] [Abstract][Full Text] [Related]
3. Nucleophosmin-anaplastic lymphoma kinase (NPM-ALK), a novel Hsp90-client tyrosine kinase: down-regulation of NPM-ALK expression and tyrosine phosphorylation in ALK(+) CD30(+) lymphoma cells by the Hsp90 antagonist 17-allylamino,17-demethoxygeldanamycin.
Bonvini P; Gastaldi T; Falini B; Rosolen A
Cancer Res; 2002 Mar; 62(5):1559-66. PubMed ID: 11888936
[TBL] [Abstract][Full Text] [Related]
4. Molecular Modeling for Structural Insights Concerning the Activation Mechanisms of F1174L and R1275Q Mutations on Anaplastic Lymphoma Kinase.
Jiang CH; Huang CX; Chen YJ; Chuang YC; Huang BY; Yang CN
Molecules; 2018 Jul; 23(7):. PubMed ID: 30004444
[TBL] [Abstract][Full Text] [Related]
5. Characterization of some molecular mechanisms governing autoactivation of the catalytic domain of the anaplastic lymphoma kinase.
Tartari CJ; Gunby RH; Coluccia AM; Sottocornola R; Cimbro B; Scapozza L; Donella-Deana A; Pinna LA; Gambacorti-Passerini C
J Biol Chem; 2008 Feb; 283(7):3743-50. PubMed ID: 18070884
[TBL] [Abstract][Full Text] [Related]
6. Crystal structures of anaplastic lymphoma kinase in complex with ATP competitive inhibitors.
Bossi RT; Saccardo MB; Ardini E; Menichincheri M; Rusconi L; Magnaghi P; Orsini P; Avanzi N; Borgia AL; Nesi M; Bandiera T; Fogliatto G; Bertrand JA
Biochemistry; 2010 Aug; 49(32):6813-25. PubMed ID: 20695522
[TBL] [Abstract][Full Text] [Related]
7. Structural insights into the ATP binding pocket of the anaplastic lymphoma kinase by site-directed mutagenesis, inhibitor binding analysis, and homology modeling.
Gunby RH; Ahmed S; Sottocornola R; Gasser M; Redaelli S; Mologni L; Tartari CJ; Belloni V; Gambacorti-Passerini C; Scapozza L
J Med Chem; 2006 Sep; 49(19):5759-68. PubMed ID: 16970400
[TBL] [Abstract][Full Text] [Related]
8. Structure of the protein tyrosine kinase domain of C-terminal Src kinase (CSK) in complex with staurosporine.
Lamers MB; Antson AA; Hubbard RE; Scott RK; Williams DH
J Mol Biol; 1999 Jan; 285(2):713-25. PubMed ID: 9878439
[TBL] [Abstract][Full Text] [Related]
9. ALK mutants in the kinase domain exhibit altered kinase activity and differential sensitivity to small molecule ALK inhibitors.
Lu L; Ghose AK; Quail MR; Albom MS; Durkin JT; Holskin BP; Angeles TS; Meyer SL; Ruggeri BA; Cheng M
Biochemistry; 2009 Apr; 48(16):3600-9. PubMed ID: 19249873
[TBL] [Abstract][Full Text] [Related]
10. The R1275Q neuroblastoma mutant and certain ATP-competitive inhibitors stabilize alternative activation loop conformations of anaplastic lymphoma kinase.
Epstein LF; Chen H; Emkey R; Whittington DA
J Biol Chem; 2012 Oct; 287(44):37447-57. PubMed ID: 22932897
[TBL] [Abstract][Full Text] [Related]
11. Oncogenic mutations of ALK kinase in neuroblastoma.
Chen Y; Takita J; Choi YL; Kato M; Ohira M; Sanada M; Wang L; Soda M; Kikuchi A; Igarashi T; Nakagawara A; Hayashi Y; Mano H; Ogawa S
Nature; 2008 Oct; 455(7215):971-4. PubMed ID: 18923524
[TBL] [Abstract][Full Text] [Related]
12. Activation loop phosphorylation modulates Bruton's tyrosine kinase (Btk) kinase domain activity.
Lin L; Czerwinski R; Kelleher K; Siegel MM; Wu P; Kriz R; Aulabaugh A; Stahl M
Biochemistry; 2009 Mar; 48(9):2021-32. PubMed ID: 19206206
[TBL] [Abstract][Full Text] [Related]
13. Role of signal transducer and activator of transcription 5 in nucleophosmin/ anaplastic lymphoma kinase-mediated malignant transformation of lymphoid cells.
Nieborowska-Skorska M; Slupianek A; Xue L; Zhang Q; Raghunath PN; Hoser G; Wasik MA; Morris SW; Skorski T
Cancer Res; 2001 Sep; 61(17):6517-23. PubMed ID: 11522649
[TBL] [Abstract][Full Text] [Related]
14. Crystal structure of a complex between protein tyrosine phosphatase 1B and the insulin receptor tyrosine kinase.
Li S; Depetris RS; Barford D; Chernoff J; Hubbard SR
Structure; 2005 Nov; 13(11):1643-51. PubMed ID: 16271887
[TBL] [Abstract][Full Text] [Related]
15. Development of anaplastic lymphoma kinase (ALK) small-molecule inhibitors for cancer therapy.
Li R; Morris SW
Med Res Rev; 2008 May; 28(3):372-412. PubMed ID: 17694547
[TBL] [Abstract][Full Text] [Related]
16. The emerging pathogenic and therapeutic importance of the anaplastic lymphoma kinase gene.
Kelleher FC; McDermott R
Eur J Cancer; 2010 Sep; 46(13):2357-68. PubMed ID: 20451371
[TBL] [Abstract][Full Text] [Related]
17. A dimeric kinase assembly underlying autophosphorylation in the p21 activated kinases.
Pirruccello M; Sondermann H; Pelton JG; Pellicena P; Hoelz A; Chernoff J; Wemmer DE; Kuriyan J
J Mol Biol; 2006 Aug; 361(2):312-26. PubMed ID: 16837009
[TBL] [Abstract][Full Text] [Related]
18. Molecular variant of the NPM-ALK rearrangement of Ki-1 lymphoma involving a cryptic ALK splice site.
Ladanyi M; Cavalchire G
Genes Chromosomes Cancer; 1996 Mar; 15(3):173-7. PubMed ID: 8721682
[TBL] [Abstract][Full Text] [Related]
19. Hydrophobic interaction between the SH2 domain and the kinase domain is required for the activation of Csk.
Mikkola ET; Gahmberg CG
J Mol Biol; 2010 Jun; 399(4):618-27. PubMed ID: 20434462
[TBL] [Abstract][Full Text] [Related]
20. Identification of NPM-ALK interacting proteins by tandem mass spectrometry.
Crockett DK; Lin Z; Elenitoba-Johnson KS; Lim MS
Oncogene; 2004 Apr; 23(15):2617-29. PubMed ID: 14968112
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
